<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551070</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00604</org_study_id>
    <secondary_id>NCI-2009-00604</secondary_id>
    <secondary_id>CDR0000563965</secondary_id>
    <secondary_id>GOG-0239</secondary_id>
    <secondary_id>GOG-0239</secondary_id>
    <secondary_id>U10CA180868</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00551070</nct_id>
  </id_info>
  <brief_title>Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer</brief_title>
  <official_title>A Phase II Trial of AZD6244 (NSC# 748727) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and how well selumetinib sulfate works in
      treating patients with low-grade ovarian cancer that has come back. Selumetinib sulfate may
      stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To examine the tumor response rate of patients on AZD6244 (selumetinib sulfate) (NSC
      #748727).

      II. To examine the acute toxicity of AZD6244 (NSC #748727) during the first course of
      treatment using Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.

      III. To define the pharmacokinetic profile for AZD6244, 100 mg administered orally twice
      daily.

      SECONDARY OBJECTIVES:

      I. To examine the toxicity of AZD6244 (NSC #748727) using the 21 major categories of the
      CTCAE version 3.0.

      II. To examine the dose and number of courses of AZD6244 (NSC #748727) given. III. To
      estimate the progression free survival, and overall survival of women receiving AZD6244 (NSC
      #748727).

      TERTIARY OBJECTIVES:

      I. To examine deoxyribonucleic acid (DNA) isolation with sequencing of b-raf proto-oncogene,
      serine/threonine kinase (braf), and retrovirus associated sequence (ras) mutation analysis
      and to explore their relationship with tumor response with AZD6244 (NSC #748727).

      II. To examine protein levels of phosphorylated mitogen-activated protein kinase 1
      (p-ERK/ERKERK) and explore their relationship with tumor response in patients treated with
      AZD6244 (NSC #748727).

      OUTLINE:

      Patients receive selumetinib sulfate orally (PO) twice a day (BID) on days 1-28. Courses
      repeat every 28 days in the absence of disease progression or unacceptable toxicity.

      Patients undergo blood sample collection periodically for correlative and pharmacokinetic
      studies and to analyze selumetinib sulfate peak concentrations and the corresponding peak
      time values. Previously collected archived tumor tissue samples are obtained to determine
      protein levels of p-ERK/ERKERK, DNA isolation and sequencing of BRAF and ras mutation
      analysis by immunohistochemistry (IHC).

      After completion of study treatment, patients are followed every 3 months for 2 years, every
      6 months for 3 years, and then once a year for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 17, 2007</start_date>
  <primary_completion_date type="Actual">July 23, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>Every other cycle</time_frame>
    <description>Complete and Partial Tumor Response by (Response Evaluation Criteria in Solid Tumors) RECIST 1.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events (Grade 3 or Higher) During First Cycle of Treatment</measure>
    <time_frame>Cycle 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) for AZD6244, 100 mg Administered Orally Twice Daily.</measure>
    <time_frame>Pre-dose, and 1, 3, and 6 hours after administration of drug on Day 7 after the start of AZD6244 treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) for AZD6244, 100 mg Administered Orally Twice Daily.</measure>
    <time_frame>Pre-dose, and 1, 3, and 6 hours after administration of drug on Day 7 after the start of AZD6244 treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Every other cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Courses Received</measure>
    <time_frame>Every cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Every cycle during treatment, then every 3 months for the first 2 years, then every six months for the next three years and then annually for the next 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Borderline Ovarian Epithelial Tumor</condition>
  <condition>Low Grade Ovarian Serous Adenocarcinoma</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <condition>Primary Peritoneal Low Grade Serous Adenocarcinoma</condition>
  <condition>Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor</condition>
  <arm_group>
    <arm_group_label>Treatment (selumetinib sulfate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive selumetinib sulfate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (selumetinib sulfate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (selumetinib sulfate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selumetinib Sulfate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (selumetinib sulfate)</arm_group_label>
    <other_name>AZD-6244 Hydrogen Sulfate</other_name>
    <other_name>AZD6244 Hydrogen Sulfate</other_name>
    <other_name>AZD6244 Hydrogen Sulphate</other_name>
    <other_name>Selumetinib Sulphate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients age greater than 18 with the following tumors are included in the study:

               -  Patients initially diagnosed with low-grade serous ovarian or peritoneal
                  carcinoma that recur as low grade serous carcinoma (invasive micropapillary
                  serous carcinoma or invasive grade I serous carcinomas as defined by Gynecologic
                  Oncology Group [GOG], International Federation of Gynecology and Obstetrics
                  [FIGO] World Health Organization [WHO] or Silverberg)

               -  Patients initially diagnosed with serous borderline ovarian or peritoneal
                  carcinoma that recur as low grade serous carcinoma (invasive micropapillary
                  serous carcinoma or invasive grade I serous carcinomas as defined by GOG, FIGO
                  WHO or Silverberg)

          -  Measurable disease defined as at least one lesion that can be accurately measured in
             at least one dimension (longest dimension to be recorded); each &quot;target&quot; lesion must
             be &gt;= 20 mm when measured by conventional techniques, including palpation, plain
             x-ray, computed tomography (CT), and magnetic resonance imaging (MRI), or &gt;= 10 mm
             when measured by spiral CT

          -  Patient must have documented low grade serous carcinoma (invasive micropapillary
             serous); confirmation must occur before patient is considered eligible for the trial

               -  Patients whose primary tumor was low-grade serous ovarian or peritoneal carcinoma
                  must have a pretreatment sample of their tumor from their primary or recurrent
                  tumor that documents low grade serous carcinoma (invasive micropapillary serous)

               -  Patients whose primary tumor was serous borderline ovarian or peritoneal
                  carcinoma must have a pretreatment sample of their tumor from their recurrent
                  tumor that documents low grade serous carcinoma (invasive micropapillary serous)

          -  Creatinine CTCAE grade 0-1 (&lt; 1.5 x upper limit of normal [ULN])

          -  Bilirubin CTCAE grade 0-1 (&lt; 1.5 x ULN)

          -  Transaminases CTCAE grade 0-1 (&lt; 2.5 x ULN)

          -  Neutrophil CTCAE grade 0-1 (&gt;= 1500/mcl)

          -  Platelets CTCAE grade 0-1 (&gt;= 100,000/mcl)

          -  Neuropathy =&lt; CTCAE grade 1

          -  No restrictions on prior therapy; patients cannot have previously received AZD6244

          -  Patients of childbearing potential must have a negative pregnancy test and must agree
             to practice an effective means of birth control prior to study entry, for the duration
             of study participation, and for four weeks after dosing with AZD6244 ceases

          -  Patients who have met the pre-entry requirements

          -  Patients must have signed an approved informed consent and authorization permitting
             release of personal health information

          -  Patients must have a GOG performance status of 0 or 1

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study or those who have not
             recovered from adverse events due to agents administered more than 4 weeks earlier

          -  Patients may not be receiving any other investigational agents

          -  Patients with known brain metastases should be excluded from this clinical trial

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to AZD6244 or its excipient Captisol

          -  Previous mitogen-activated protein kinase (MEK) inhibitor use

          -  Patients with corrected QT (QTc) interval &gt; 450 msecs or other factors that increase
             the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia,
             family history of long QT interval syndrome) including heart failure that meets New
             York Heart Association (NYHA) class III and IV definitions are excluded
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Farley</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute Palo Alto</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital of Central Connecticut</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beebe Medical Center</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System-Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hinsdale Hematology Oncology Associates Incorporated</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital and Health Care Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center-Bramhall Campus</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital of Cecil County</name>
      <address>
        <city>Elkton</city>
        <state>Maryland</state>
        <zip>21921</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Battle Creek</name>
      <address>
        <city>Battle Creek</city>
        <state>Michigan</state>
        <zip>49017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Big Rapids Hospital</name>
      <address>
        <city>Big Rapids</city>
        <state>Michigan</state>
        <zip>49307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Consortium of West Michigan NCORP</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Saint Mary's</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health at Butterworth Campus</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holland Community Hospital</name>
      <address>
        <city>Holland</city>
        <state>Michigan</state>
        <zip>49423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Partners-Hackley Campus</name>
      <address>
        <city>Muskegon</city>
        <state>Michigan</state>
        <zip>49442</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Mercy Campus</name>
      <address>
        <city>Muskegon</city>
        <state>Michigan</state>
        <zip>49444</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munson Medical Center</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Health Hospital</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research for the Ozarks NCORP</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CoxHealth South Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Hospital University Medical Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center/Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Presbyterian Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynecologic Oncology Network</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center/Fairview Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Carmel Health Center West</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Valley Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Hospital Cancer Center</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake University Ireland Cancer Center</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cancer Specialists and Research Institute-Tulsa</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2007</study_first_submitted>
  <study_first_submitted_qc>October 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <results_first_submitted>June 10, 2015</results_first_submitted>
  <results_first_submitted_qc>June 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 29, 2015</results_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was activated on 9/22/2008 and closed to accrual on 1/31/2011 (suspended from 1/4/2010 to 8/9/2010).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD6244</title>
          <description>AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eligible and treated patients.</population>
      <group_list>
        <group group_id="B1">
          <title>AZD6244</title>
          <description>AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>20-29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-89 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tumor Response</title>
        <description>Complete and Partial Tumor Response by (Response Evaluation Criteria in Solid Tumors) RECIST 1.0</description>
        <time_frame>Every other cycle</time_frame>
        <population>Eligible and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6244</title>
            <description>AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response</title>
          <description>Complete and Partial Tumor Response by (Response Evaluation Criteria in Solid Tumors) RECIST 1.0</description>
          <population>Eligible and treated patients</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" lower_limit="7.9" upper_limit="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>Every other cycle</time_frame>
        <population>Eligible and Treated Patients</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6244</title>
            <description>AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <population>Eligible and Treated Patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="6.2" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Courses Received</title>
        <time_frame>Every cycle</time_frame>
        <population>Eligible and Treated Patients. Two patients still on study and have received 68 and 79 cycles of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6244</title>
            <description>AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Courses Received</title>
          <population>Eligible and Treated Patients. Two patients still on study and have received 68 and 79 cycles of treatment.</population>
          <units>courses</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events (Grade 3 or Higher) During First Cycle of Treatment</title>
        <time_frame>Cycle 1</time_frame>
        <population>Eligible and treated patients.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6244</title>
            <description>AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (Grade 3 or Higher) During First Cycle of Treatment</title>
          <population>Eligible and treated patients.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergy/Immunology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Auditory/Ear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coagulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constitutional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dermatologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="4" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="6" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary/Renal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphatics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurosensory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Neurological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ocular/Visual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) for AZD6244, 100 mg Administered Orally Twice Daily.</title>
        <time_frame>Pre-dose, and 1, 3, and 6 hours after administration of drug on Day 7 after the start of AZD6244 treatment</time_frame>
        <population>Eligible and Treated Patients with all pharmacokinetic time points available</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6244</title>
            <description>AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for AZD6244, 100 mg Administered Orally Twice Daily.</title>
          <population>Eligible and Treated Patients with all pharmacokinetic time points available</population>
          <units>ng x hr/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2419" lower_limit="1673" upper_limit="3186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) for AZD6244, 100 mg Administered Orally Twice Daily.</title>
        <time_frame>Pre-dose, and 1, 3, and 6 hours after administration of drug on Day 7 after the start of AZD6244 treatment</time_frame>
        <population>Eligible and Treated Patients with at least one post-dose pharmacokinetic time point available</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6244</title>
            <description>AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) for AZD6244, 100 mg Administered Orally Twice Daily.</title>
          <population>Eligible and Treated Patients with at least one post-dose pharmacokinetic time point available</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="585" lower_limit="371" upper_limit="1100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>Every cycle during treatment, then every 3 months for the first 2 years, then every six months for the next three years and then annually for the next 5 years</time_frame>
        <population>Eligible and Treated Patients</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6244</title>
            <description>AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>Eligible and Treated Patients</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" lower_limit="17.7" upper_limit="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study Treatment</time_frame>
      <desc>Includes all adverse events reported (grade 1-5) regardless of attribution.</desc>
      <group_list>
        <group group_id="E1">
          <title>AZD6244</title>
          <description>AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Prolonged Qtc Interval</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>S/N Arrhythmia: Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcer,gi - Esophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Obstruction, Gi - Colon</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Mucositis (Functional/Sympt) - Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Obstruction, Gi - Small Bowel Nos</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Mucositis (Clinical Exam) - Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Stricture, Gi - Biliary Tree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Death No Ctcae Term - Disease Progression Nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Throat/Pharynx/Larynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Abdominal Pain Nos</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Lung(Pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Skin(Cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Inf Unknown Anc: Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Mood Alteration - Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ards</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, Gi - Rectum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Thrombosis/Thrombus/Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood/Bone Marrow - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Edema: Head And Neck</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Prolonged Qtc Interval</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>S/N Arrhythmia: Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Watery Eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Obstruction, Gi - Ileum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Distention</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Taste Alteration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Mucositis (Functional/Sympt) - Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Mucositis (Clinical Exam) - Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Mucositis (Clinical Exam) - Esophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rigors/Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Urethra</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Chest /Thorax Nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Throat/Pharynx/Larynx</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Head/Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Intestine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Extremity-Limb</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Back</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Joint</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Pain Nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Abdominal Pain Nos</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Cardiac/ Heart</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Muscle</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Anus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain: Sinus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction/Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Vulva</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Upper Airway Nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Skin(Cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Urinary Tract Nos</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Ungual (Nails)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Pharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Vagina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Inf Unknown Anc: Pharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Inf Unknown Anc: Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Inf Unknown Anc: Skin (Cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Bladder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Ast</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ggt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Alt</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Muscle Weakness - Whole Body/Generalized</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Mood Alteration - Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Mood Alteration - Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Speech Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cognitive Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Neuropathy-Sensory</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/Genitourinary - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Obstruction, Gu - Ureter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Incontinence, Urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urinary Frequency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary: Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Voice Changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nail Changes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hair Loss/Alopecia (Scalp Or Body)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypopigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hand-Foot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Inr</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Gu - Urinary Nos</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Gu - Vagina</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Pulmonary - Bronchopulmonary Nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Gi - Rectum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Pulmonary - Nose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Gi - Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Gu - Bladder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Gi - Colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Thrombosis/Thrombus/Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study began with 100mg BID mix &amp; drink (MD) formulation. AstraZeneca (AZ) switched to hydrogen-sulfate capsule (HC). AZ deemed 100mg BID MD equivalent to 50mg BID HC. As of 12/31/2010, patients got 50mg BID HC; four patients were on treatment then.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Angela M. Kuras, Associate Director of Data Management</name_or_title>
      <organization>NRG Oncology Statistics and Data Management Center - Buffalo</organization>
      <phone>716-845-7733</phone>
      <email>kurasa@nrgoncology.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

